Applying for H2020-PM-03 or PM-11 calls? EATRIS can support your partner search !

Published 9 December 2016

Tags , , ,

Do you plan on submitting a H2020 proposal under one of these two calls?

EATRIS can provide access to the following relevant services you could be looking for (list non exhaustive):

  • SC1-PM-03-2016:
    • Access to rare diseases patient cohorts and clinical expertise;
    • Access to clinical samples and biobanks for well annotated clinical data;
    • Wide array of technology platforms including genomics, proteomics and metabolomics with state of the art facilities;
    • Single point of access from marker identification, collection to analytical testing, assay development and validation;
    • Support for experimental design and development plan;
    • Data stewardship.
  • SC1-PM-11-2017:
    • Access to wide range of small to large in vivo models;
    • Access to appropriate informative animal models suitable for generating pharmacology data for ATMP translation into clinical use, for a large array of disease conditions, including rare diseases, neurology, oncology, cardiovascular, immunology, neuromuscular, metabolic / degenerative;
    • Access to appropriate informative animal models suitable for generating GLP compliant toxicology data for ATMP translation into clinical use;
    • Support for preclinical studies design according to applicable regulatory requirements;
    • Dedicated translational support teams for rapid development of preclinical program, including documentation;
    • Preclinical testing capabilities, including routine analyses, microbiology, biochemistry, functional tests, molecular biology, flow cytometry, immune-monitoring, viral vectors generation, and clinical imaging for small animals.

For more information on EATRIS ‘Fast Matchmaking’, please contact Anne-Charlotte: